Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) – Equities research analysts at Zacks Research issued their FY2025 earnings per share estimates for shares of Corcept Therapeutics in a research note issued on Tuesday, March 14th. Zacks Research analyst E. Bagri forecasts that the biotechnology company will post earnings of $1.03 per share for the year. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.86 per share.
Several other research firms also recently issued reports on CORT. Jefferies Financial Group downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $35.00 to $22.00 in a research note on Wednesday, February 15th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Corcept Therapeutics in a report on Wednesday, March 1st. StockNews.com started coverage on Corcept Therapeutics in a report on Thursday. They set a “buy” rating for the company. Finally, Canaccord Genuity Group decreased their price objective on Corcept Therapeutics from $33.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.50.
Corcept Therapeutics Stock Down 1.0 %
Corcept Therapeutics (NASDAQ:CORT – Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.09). Corcept Therapeutics had a return on equity of 22.20% and a net margin of 25.21%. The company had revenue of $103.06 million for the quarter, compared to the consensus estimate of $106.93 million. During the same quarter in the previous year, the company earned $0.26 earnings per share. Corcept Therapeutics’s quarterly revenue was up 4.3% compared to the same quarter last year.
Hedge Funds Weigh In On Corcept Therapeutics
A number of large investors have recently made changes to their positions in CORT. Federated Hermes Inc. lifted its stake in Corcept Therapeutics by 16.8% during the second quarter. Federated Hermes Inc. now owns 5,537,000 shares of the biotechnology company’s stock worth $131,670,000 after purchasing an additional 796,580 shares during the last quarter. Norges Bank acquired a new stake in Corcept Therapeutics during the 4th quarter worth about $15,648,000. BlackRock Inc. grew its holdings in Corcept Therapeutics by 4.7% during the 3rd quarter. BlackRock Inc. now owns 16,187,049 shares of the biotechnology company’s stock worth $415,037,000 after acquiring an additional 719,416 shares during the period. Boston Trust Walden Corp grew its holdings in Corcept Therapeutics by 35.9% during the 4th quarter. Boston Trust Walden Corp now owns 1,846,281 shares of the biotechnology company’s stock worth $37,498,000 after acquiring an additional 487,962 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Corcept Therapeutics by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 10,332,077 shares of the biotechnology company’s stock valued at $264,915,000 after buying an additional 458,414 shares during the period. Institutional investors own 80.08% of the company’s stock.
Corcept Therapeutics Company Profile
Corcept Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol.
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.